97 Views
Monday Poster Session
Category: Obesity
Pichamol Jirapinyo, MD, MPH
Brigham & Women's Hospital
Boston, MA, United States
TORe + Pharmacotherapy (n = 100) | Pharmacotherapy Alone (n = 211) | TORe Alone (n = 304) | Surgical Revision of GJA (n = 77) | |
Demographics | ||||
Age (years) | 49 ± 11 | 47 ± 10 | 50 ± 11 | 50 ± 9 |
Sex (female, %) | 90 | 91 | 86 | 70 |
BMI (kg/m2) | 40.2 ± 8.0 | 38.7 ± 8.0 | 39.2 ± 8.4 | 42.6 ± 10.8 |
Amount of weight regain (% of maximal lost weight) | 62.3 ± 65.7 | 44.8 ± 28.2 | 51.0 ± 44.4 | 53.6 ± 29.3 |
Efficacy and Safety | ||||
TWL at 12 months (%) | 16.2 ± 6.7 | 6.8 ± 8.2 | 8.7 ± 8.1 | 16.4 ± 13.1 |
≥5% TWL at 12 months (%) | 96.6 | 63.0 | 66.3 | 80.6 |
Serious adverse events (%) | 4 - GJA stenosis (3) - Pneumonia | 6.6 - CNS effects (10) - Blurry vision (2) - GI bleeding (2) | 2.6 - GJA stenosis (7) - GI bleeding | 18.2 - Leak (3) - Infected wound (3) - GJA stenosis (2) - Subcutaneous emphysema - Pleural effusion - Pancreatitis - Pulmonary embolism - Pneumonia - SBO |